Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/
Eloxatin (Oxaliplatin) – US: District Court New Jersey grants summary judgment of non-infringement in favour of Hospira, Teva and others concerning patent relating to Sanofi’s Eloxatin: Sanofi-Aventis v Sandoz (SmartBrief) (The IP Factor) (GenericsWeb) (Patents4Life)
Europe’s ever changing landscape Pirate Party, Loi Hadopi and generic drug seizures IP Think Tank podcast 15 June 2009 (IP Think Tank)
WCO considers new ‘dialogue mechanism’ on counterfeiting, explicit focus on public health (Intellectual Property Watch)
Talks on traditional knowledge and access, benefit-sharing – Hyderabad, 16-19 June (Intellectual Property Watch)
Canada: Utility under Canadian patent law and the doctrine of sound prediction: Apotex v Wellcome Foundation (Patent Docs)
EU: Adopted codified version of Council Regulation 1768/92 concerning SPCs now published (The SPC Blog)
UN Special Rapporteur: IP in health helping those with most means, less need (Intellectual Property Watch)
US: Gene patenting debate: UCLA v USPTO (IP Watchdog) (Inventive Step) (IP Watchdog)
US: History of gene patents (Part 1 – IP Watchdog)
US: Biotechnology, biologistics and biobusiness in Kentucky (Patent Baristas)
US: Future drug sales predictions highlight importance of follow-on biologics legislation (Patent Docs)
US: BIO to USA Today: Patents promote innovation (PatentlyBIOtech)
US: AEI believes advantages of longer data exclusivity period outweigh disadvantages (Patent Docs)
Cipro (Ciprofloxacin) – US: Supreme Court rejects lawsuit challenging Bayer’s deal with Barr to delay generic Cipro (GenericsWeb)
Eloxatin (Oxaliplatin) – US: District Court New Jersey grants summary judgment of non-infringement in favour of Hospira, Teva and others concerning patent relating to Sanofi’s Eloxatin: Sanofi-Aventis v Sandoz (SmartBrief) (The IP Factor) (GenericsWeb) (Patents4Life)
Fosamax (Alendronate) – Canada: Federal Court of Appeal’s decision interpreting s 8 Patented Medicines (Notice of Compliance) Regulations leads to mixed results: Merck Frosst Canada Ltd and Merck Frosst Canada & Co v Apotex Inc (IP Osgoode)
Lipitor (Atorvastatin) – US: Pfizer files patent suits against Mylan over generic Lipitor ANDA (Patent Docs)
Lyrica (Pregabalin) – US: Pfizer adds second patent to Lyrica infringement suit against Sun Pharma (Patent Docs) (GenericsWeb)
Nuvaring (Etonogestrel, Ethinyloestradiol) – Australia: Patent Office allows patent term extension for a drug delivery system for two or more active substances: N V Organon (The SPC Blog)
OxyContin (Oxycodone) – US: KV, Purdue settle OxyContin litigation (Patent Docs)
Paxil (Paroxetine) – Israel Patent Office voids SmithKline Beecham patent for metastable polymorph (The IP Factor)
Roundup Ready – US: DuPont countersues Monsanto in dispute over Roundup Ready technology (Patent Docs)
Solodyn (Minocyclene) – US: Medicis files infringement suit against Ranbaxy over Solodyn patents (Patent Docs)
Tri-Cylcen Lo (Norestimate, Ethinyl estradiol) – US: Ortho-McNeil-Janssen files patent infringement suit against Sandoz in response to generic Tri-Cyclen Lo ANDA (Patent Docs) (GenericsWeb)
Tylenol (Acetominophen) – US: Public Patent Foundation files suit against McNeil-PPC alleging false marking on Tylenol products (Patent Docs)
Xyzal (Levoctirizine) – US: Sepracor files patent infringement suit against Synthon over generic Xyzal ANDA (Patent Docs)